Urate and homocysteine: Changes in motor and cognitive symptoms in newly diagnosed Parkinson’s disease
Objective: 1) To determine serum urate and homocysteine concentration at baseline, 18 and 36 months in control and PD participants. 2) To determine if urate…Comparison of Test Your Memory (TYM) and Montreal Cognitive Assessment (MoCA) measures in Parkinson’s disease
Objective: We sought to determine: a) the ability of TYM to discriminate between PD patients with and without cognitive deficits b) equivalence between MoCA scores…Neuro-cognitive domain related to conversion of Parkinson’s disease dementia
Objective: To identify neurocognitive domain and mild cognitive impairment (MCI) subtype associated with conversion from non-demented patients with Parkinson's disease (PD) and PD-MCI to dementia…Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia
Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…Dementia in Parkinson’s disease is associated with increased diffusivity in amygdala and external capsule
Objective: To identify which regions are associated with dementia in Parkinson's disease (PD) brains. Background: Dementia is common in advanced PD and its early development…Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the MPTP mouse model of Parkinson’s disease
Objective: To evaluate cerebral hypoperfusion on cognitive dysfunction and related microvascular impairment in the MPTP mouse model. Background: Vascular pathology and Parkinson's disease (PD) pathology…FYN expression is associated with regulatory region genetic variation
Objective: The hypothesis of this investigation was that FYN expression and promoter activity are significantly influenced according to genetic content. The objective of this investigation…Visual hallucinations may serve as a possible predictor for Parkinson’s disease dementia
Objective: To observe whether visual hallucinations serve as a predictor of Parkinson's disease dementia. Background: Visual hallucinations (VH) is one of non-motor symptoms in Parkinson's…Combinative therapy of memantine and galantamine hydrobromide as a tool of choice for the treatment of vascular parkinsonism with early appearance of dementia symptoms
Objective: Our primary aim was comparative study of monotherapy with memantine and combinative therapy with memantine and galantamine hydrobromide for treatment of vascular parkinsonism with…Cognitive profile in the Parkinsonian variant of multiple system atrophy: Findings from a Tunisian cohort
Objective: To establish the cognitive profile of MSA-P in a Tunisian cohort and to discuss its association with motor signs. Background: It has been previously…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 33
- Next Page »